Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)

被引：0
|
作者：
Loriot, Yohann
Matsubara, Nobuaki
Park, Se Hoon
Huddart, Robert A.
Burgess, Earle F.
Houede, Nadine
Banek, Severine
Laguerre, Brigitte
Guadalupi, Valentina
Ku, Ja Hyeon
Triantos, Spyros
Akapame, Sydney
Deprince, Kris
Mukhopadhyay, Sutapa
Siefker-Radtke, Arlene O.
机构：
[1] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, INSERM 981, Villejuif, France
[2] Natl Canc Ctr Hosp East, Dept Med Oncol, Chiba, Japan
[3] Sungkyunkwan Univ, Samsung Med Ctr, Gangnam, South Korea
[4] Inst Canc Res, Sect Radiotherapy & Imaging, Sutton, Surrey, England
[5] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[6] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[7] CHU Caremeau, Inst Cancerol Gard, Dept Med Oncol, Nimes, France
[8] Goethe Univ, Univ Hosp Frankfurt, Dept Urol, Frankfurt, Germany
[9] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France
[10] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[11] Seoul Natl Univ Hosp, Seoul, South Korea
[12] Janssen Res & Dev, Spring House, PA USA
[13] Janssen Res & Dev, Beerse, Belgium
[14] Janssen Res & Dev, Lexington, MA USA
[15] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA4619
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Sequencing of erdafitinib (erda) and enfortumab vedotin (EV) in patients (pts) with fibroblast growth factor receptor (FGFR2/3) altered (alt) advanced urothelial cancer (aUC): Analysis of UNITE database
    Jiang, Cindy Y.
    Hwang, Hyunsoo
    Jindal, Tanya
    Qiao, Wei
    Epstein, Ilana
    Nguyen, Charles B.
    Gupta, Shilpa
    Shah, Sumit
    Bilen, Mehmet Asim
    Milowsky, Matthew I.
    Hoimes, Christopher J.
    Kilari, Deepak
    Zakharia, Yousef
    Emamekhoo, Hamid
    Grivas, Petros
    Bellmunt, Joaquim
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    Campbell, Matthew T.
    Alhalabi, Omar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL)
  • [22] Fibroblast growth factor receptor alteration (FGFRα) status and progression outcomes of patients with advanced or metastatic urothelial cancer (mUC).
    Fleming, Sarah
    Gifkins, Dina
    Shalaby, Waleed
    Gao, Jianjun
    Rosenberg, Philip
    Gaj, Christopher
    Crawford, Albert
    Lu-Yao, Grace L.
    Maio, Vittorio
    Siefker-Radtke, Arlene O.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] MSK-ACCESS for the detection of fibroblast growth factor receptor-3 (FGFR3) mutations in plasma cell-free (cf)DNA of metastatic urothelial carcinoma (mUC) patients (pts) pre- and on erdafitinib (erda) therapy.
    Sarfaty, Michal
    Teo, Min Yuen
    Funt, Samuel Aaron
    Lee, Chung-Han
    Aggen, David Henry
    Ratna, Neha
    Regazzi, Ashley Marie
    Al-Ahmadie, Hikmat
    Brannon, Angela Rose
    Berger, Michael F.
    Solit, David B.
    Rosenberg, Jonathan E.
    Bajorin, Dean F.
    Iyer, Gopa
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Are fibroblast growth factor receptor 3 (FGFR3) alterations a possible predictive factor for platinum-based chemotherapy and immunotherapy in metastatic urothelial carcinoma (MUC)?
    Ferrer-Mileo, L.
    Rodriguez Hernandez, A.
    Aversa, C.
    Rodriguez-Carunchio, L.
    Ribera, I.
    Trias Puigsureda, I.
    Oliva, L.
    Jimenez Blasco, N.
    Garcia-Esteve, S.
    Alvarez, M.
    Rabella, M.
    Mellado Gonzalez, B.
    Reig Torras, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S1220 - S1221
  • [25] Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations
    Pal, Sumanta K.
    Rosenberg, Jonathan E.
    Keam, Bhumsuk
    Wolf, Juergen
    Berger, Raanan
    Dittrich, Christian
    Hoffman-Censits, Jean H.
    Quinn, David
    van der Noll, Ruud
    Burris, Howard A.
    Galsky, Matt D.
    Gravis, Gwenaelle
    Lee, Jae-Lyun
    Medioni, Jacques
    Mortazavi, Amir
    Maroto, Pablo
    Parker, Katie
    Chen, Xueying
    Isaacs, Randi
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Clinical Performance of QIAGEN Fibroblast Growth Factor Receptor (FGFR) Assay for the Detection of FGFR Alterations in Erdafitinib-Treated Patients with Metastatic or Locally Advanced, Surgically Unresectable, Urothelial Cancer
    Major, C.
    Wang, S.
    Burgess, M.
    English, A.
    Sweeney, M.
    Hartmann, A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2019, 21 (03): : S57 - S57
  • [27] Phase II, open-label study of erdafitinib in adult and adolescent patients (pts) with advanced solid tumours harboring fibroblast growth factor receptor (FGFR) gene alterations
    Schuler, M.
    Tabernero, J.
    Massard, C.
    Iyer, G. Vasudeva
    Witt, O.
    Doi, T.
    Qin, S.
    Lu-Emerson, C.
    Hargrave, D.
    Garcia-Corbacho, J.
    Little, S.
    Xia, Q.
    Santiago-Walker, A.
    Moy, C. H.
    Hammond, C.
    Lau, Y. Y.
    Sweiti, H.
    Pant, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S502 - S503
  • [28] Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma
    Soria, J-C.
    Italiano, A.
    Cervantes, A.
    Tabernero, J.
    Infante, J.
    Lara, P. N.
    Spira, A.
    Calvo, E.
    Moreno, V.
    Blay, J-Y.
    Lauer, R.
    Chan, N.
    Zhong, B.
    Santiago-Walker, A. Ademi
    Bussolari, J.
    Luo, F. R.
    Xie, H.
    Hammerman, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Erdafitinib (ERDA) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC): Subgroup analyses of long-term efficacy outcomes of a pivotal phase II trial (BLC2001)
    Necchi, A.
    Siefker-Radtke, A. O.
    Loriot, Y.
    Park, S. H.
    Garcia-Donas, J.
    Huddart, R. A.
    Burgess, E. F.
    Fleming, M. T.
    Rezazadeh, A.
    Mellado, B.
    Varlamov, S.
    Joshi, M.
    Duran, I.
    Zakharia, Y.
    Fu, M.
    Santiago-Walker, A.
    O'Hagan, A.
    Monga, M.
    Tagawa, S. T.
    ANNALS OF ONCOLOGY, 2020, 31 : S583 - S583
  • [30] Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients (pts) with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) alterations
    Feng, Yin-Hsun
    Su, Wu-Chou
    Oh, Do-Youn
    Shen, Lin
    Kim, Kyu-Pyo
    Liu, Xiufeng
    Liao, Huimin
    Qing, Min
    Qian, Jiaqi
    Triantos, Spyros
    Sweiti, Hussein
    Park, Joon Oh
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345